NEU neuren pharmaceuticals limited

The Whens and Whys of Top Biotech M&A Deals, page-32

  1. 451 Posts.
    lightbulb Created with Sketch. 204
    I dont disagree with your analysis other than to say paying a higher premium makes it a lot harder for the acquirer to get the necessary support from their shareholders. Perceptions matter and the acquiring company would need to convince their shareholders and analysts that they havent overpaid and that the deal is a good one. Certainly no matter how much the DCF stands up, there would be shareholders pushing back against a large premium. So in my view, the current share price matters a lot. Selling a 100% premium vs a 600% premium to their shareholders would be vastly different in my view. Of course if the company is private then it doesnt matter as much.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.07
Change
0.070(0.50%)
Mkt cap ! $1.750B
Open High Low Value Volume
$14.09 $14.19 $13.76 $788.6K 56.19K

Buyers (Bids)

No. Vol. Price($)
7 188 $14.06
 

Sellers (Offers)

Price($) Vol. No.
$14.08 265 3
View Market Depth
Last trade - 10.59am 03/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.